HomeMarket NewsMicro Cap StocksBiodexa Pharmaceuticals Stock Tumbles Following Public Offering Announcement

Biodexa Pharmaceuticals Stock Tumbles Following Public Offering Announcement

Actionable Trade Ideas

always free

eye 5248678

Biodexa Pharmaceuticals PLC-ADR BDRXΒ is experiencing a rough morning, with its shares plunging by 6.8% to $4.76 after the company’s announcement of a public offering of Class A Units at a lower-than-expected price. Investors seem to be reacting negatively to this news revealed in a preliminary prospectus.

The downward spiral began after the company unveiled its acquisition of the rights to tolimidone, an experimental drug originally developed by Pfizer Inc. for gastric ulcers. Despite this positive news, the stock took a significant hit, closing yesterday 83% higher following the announcement.

Breaking It Down

Biodexa Pharmaceuticals made a groundbreaking discovery, uncovering that tolimidone, an activator of the lyn kinase enzyme, could potentially be beneficial in treating Type-1 diabetes by safeguarding and stimulating insulin-producing beta cells. The company is now preparing for a Phase II study involving Type-1 diabetes patients to substantiate the drug’s efficacy.

See Also:Β Nasdaq, S&P 500 Futures Flatline As Traders Play Waiting Game Ahead Of Key Data

Additionally, Biodexa’s collaboration with Adhera includes an initial payment and future payments dependent on various milestones. The company has committed to issuing shares to Melior and Bukwang, as well as offering royalties on tolimidone sales.

The finalization of the transaction hinges on specific conditions and is projected to be completed in the fourth quarter of 2023.

Data fromΒ Benzinga Pro reveals that BDRX hit a 52-week high of $579.20 and a 52-week low of $2.26.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.